18 research outputs found
Production of Medical Radioisotopes with High Specific Activity in Photonuclear Reactions with Beams of High Intensity and Large Brilliance
We study the production of radioisotopes for nuclear medicine in
photonuclear reactions or ()
photoexcitation reactions with high flux [()/s], small
diameter m and small band width () beams produced by Compton back-scattering of laser
light from relativistic brilliant electron beams. We compare them to (ion,np) reactions with (ion=p,d,) from particle accelerators like
cyclotrons and (n,) or (n,f) reactions from nuclear reactors. For
photonuclear reactions with a narrow beam the energy deposition in the
target can be managed by using a stack of thin target foils or wires, hence
avoiding direct stopping of the Compton and pair electrons (positrons).
isomer production via specially selected cascades
allows to produce high specific activity in multiple excitations, where no
back-pumping of the isomer to the ground state occurs. We discuss in detail
many specific radioisotopes for diagnostics and therapy applications.
Photonuclear reactions with beams allow to produce certain
radioisotopes, e.g. Sc, Ti, Cu, Pd, Sn,
Er, Pt or Ac, with higher specific activity and/or
more economically than with classical methods. This will open the way for
completely new clinical applications of radioisotopes. For example Pt
could be used to verify the patient's response to chemotherapy with platinum
compounds before a complete treatment is performed. Also innovative isotopes
like Sc, Cu and Ac could be produced for the first time
in sufficient quantities for large-scale application in targeted radionuclide
therapy.Comment: submitted to Appl. Phys.
Canadian 2003 international consensus algorithm for the diagnosis, therapy, and management of hereditary angioedema
C1 inhibitor deficiency (hereditary angioedema [HAE]) is a rare disorder for which there is a lack of consensus concerning diagnosis, therapy, and management, particularly in Canada. European initiatives have driven the approach to managing HAE with 3 C1-INH Deficiency Workshops held every 2 years in Hungary starting in 1999, with the third Workshop having recently been held in May 2003. The European Contact Board has established a European HAE Registry that will hopefully advance our knowledge of this disorder. The Canadian Hereditary Angioedema Society/Societe d'Angioedeme Hereditaire du Canada organized a Canadian International Consensus Conference held in Toronto, Ontario, Canada, on October 24 to 26, 2003, to foster consensus between major European and North American HAE treatment centers. Papers were presented by investigators from Europe and North America, and this consensus algorithm approach was discussed. There is a paucity of double-blind placebo-controlled trials in the treatment of HAE, making levels of evidence to support the algorithm less than optimal. Enclosed is the consensus algorithm approach recommended for the diagnosis, therapy, and management of HAE and agreed to by the authors of this article. This document is only a consensus algorithm approach and requires validation. As such, participants agreed to make this a living 2003 algorithm (ie, a work in progress) and agreed to review its content at future international HAE meetings. The consensus, however, has strength in that it was arrived at by the meeting of patient-care providers along with patient group representatives and individual patients reviewing information available to date and reaching agreement on how to approach the diagnosis, therapy, and management of HAE circa 2003. Hopefully evidence to support approaches to the management of HAE will approach the level of meta-analysis of randomized controlled trials in the near futur